KALA · KALA BIO, Inc.
$0.66
-0.01 (-0.79%)
At close · Jul 29
Market Cap
$12.27M
Shares
18.59M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | CEO | $1,491,187 |
| Todd Bazemore | CEO | $949,550 |
| Kim Brazzell | Chief Medical Officer | $920,687 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | CEO | $8,342,714 |
| Todd Bazemore | CEO | $2,943,656 |
| Kim Brazzell | Chief Medical Officer | $2,923,073 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | CEO | $1,868,299 |
| Todd Bazemore | COO | $1,025,817 |
| Kim Brazzell | Chief Medical Officer | $993,689 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | CEO | $2,772,056 |
| Todd Bazemore | COO | $1,343,356 |
| Kim Brazzell | Chief Medical Officer | $1,316,969 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Lazar | member of the Board of Directors | Resigned | 2026-02-20 |
| Avi Minkowitz | Chief Financial Officer | Appointed | 2026-02-05 |
| Avi Minkowitz | Chief Executive Officer | Appointed | 2026-02-05 |
| David Lazar | Chief Financial Officer | Resigned | 2026-02-05 |
| David Lazar | Chief Executive Officer | Resigned | 2026-02-05 |